The activities and protein content of extracellular signal-regulated kinase (ERK)1/2 in the heart were measured in rats at 4 and 16 weeks after volume overload due to aortocaval shunt. Protein content of phosphorylated ERK1/2 was increased at both 4 and 16 weeks, whereas protein content of total ERK1/2 was increased only at 16 weeks of inducing volume overload. The ERK1/2 activities, estimated as phospho-Elk-1 content, were also increased at 4 and 16 weeks of inducing volume overload. The increased phosphorylated ERK1/2 and E-26-like (Elk)-1 protein content in 16 weeks failing hearts was much greater than that in 4 weeks hypertrophied hearts. These changes in phosphorylated ERK1/2 and Elk-1 protein content in both 4 and 16 weeks volume overloaded animals were attenuated by treatment with enalapril and/or losartan. The results indicate that activation of ERK1/2 may be involved in the development of cardiac hypertrophy and heart failure due to volume overload, and these changes are partially prevented by blockade of the renin—angiotensin system (RAS).
Schluter KD, Piper HMRegulation of growth in the adult cardiomyocytes. FASEB J.1999;13(suppl):S17-S22.
2.
Bogoyevitch MA, Andersson MB, Gillespie-Brown J., et al. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy . Biochem J. 1996;314(pt 1):115-121.
3.
Shimizu N., Yoshiyama M., Omura T., et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res . 1998;38(1):116-124.
4.
Kim S., Iwao H.Activation of mitogen-activated protein kinases in cardiovascular hypertrophy and remodeling. Jpn J Pharmacol. 1999;80(2):97-102.
5.
Ma XL, Kumar S., Gao F., et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation. 1999;99(13):1685-1691.
6.
Wollert KC, Drexler H.The rennin-angiotensin system and experimental heart failure. Cardiovas Res. 1999;43(4):838-849.
7.
Yoshida K., Yoshiyama M., Omura T., et al. Activation of mitogen-activated protein kinases in the non-ischemic myocardium of an acute myocardial infarction in rats. Jpn Circ J. 2001;65(9):808-814.
8.
Bogoyevitch MA, Sugden PHThe role of protein kinases in adaptational growth of the heart. Int J Biochem Cell Biol. 1996;28(1):1-12.
9.
Ruzicka M., Yuan B., Harmsen E., Leenen FHThe reninangiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993;87(3): 921-930.
10.
Ruzicka M., Leenen FHRelevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation. 1995;91(1):16-19.
11.
Garcia R., Diebold S.Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990; 24(5):430-432.
12.
Wang X., Ren B., Liu S., Sentex E., Tappia PS, Dhalla NSCharacterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol. 2003;94(2):752-763.
13.
Xu YJ, Chapman D., Dixon IM, et al. Differential gene expression in infarct scar and viable myocardium from rat heart following coronary ligation. J Cell Mol Med . 2004;8(1):85-92.
14.
Xu YJ, Saini HK, Zhang M., Elimban V., Dhalla NSMAPK activation and apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine. Cardiovasc Res. 2006;72(1):163-174.
15.
Bradford MMA rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
16.
Gille H., Kortenjann M., Thomae O., et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J. 1995 ;14(5):951-962.
17.
Huang M., LeBlanc MH, Hester RLEvaluation of the needle technique for producing an arteriovenous fistula . J Appl Physiol. 1994;77(6):2907-2911.
18.
Huang M., Hester RL, Guyton ACHemodynamic changes in rats after opening an arteriovenous fistula. Am J Physiol Heart Circ Physiol. 1992;262(3 pt 2):H846-H851.
19.
Sadoshima JI, Malhotra R., Izumo S.The role of the cardiac rennin-angiotensin system in load-induced cardiac hypertrophy. J Cardiac Failure. 1996;2(4 suppl):S1-S6.
20.
Yano M., Kim S., Izumi Y., Yamanaka S., Iwao H.Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res. 1998;83(7):752-760.
21.
Marais R., Wynne J., Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell. 1993 ;73(2):381-393.
22.
Lou H., Danielson I., Singal PKInvolvement of mitogen activated protein kinases in adriaycin-induced cardiomyopathy . Am J Physiol Heart Circ Physiol. 2005;2884(): H1925-H1930.
23.
Bueno OF, Molkentin JDInvolvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res. 2002;91(9):776-781.
24.
Dent MR, Das S., Dhalla NSAlterations in both death and survival signals for apoptosis in heart failure due to volume overload. J Mol Cell Cardiol. 2007;43(6):726-732.
25.
Pfeffer MA, Braunwald E.Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990 ;81(4):1161-1172.
26.
Rumberger JAVentricular dilatation and remodeling after myocardial infarction. Mayo Clin Proc. 1994 ;69(7):664-674.
27.
Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 1991;4(4 pt 2):334S-340S.
28.
Schunkert H. , Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BHIncreased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86(6): 1913-1920.
29.
Dhalla NS, Shao Q., Panagia V.Remodeling of cardiac membranes during the development of congestive heart failure. Heart Fail Rev. 1998;2(4):261-272.
AokiH.,RichmondM.,IzumoS.,SadoshimaJ.Specificroleoftheextracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J. 2000;347(pt 1):275-284.
32.
Yamazaki T. , Komuro I., Shiojima I., Yazaki Y.Angiotensin II mediates mechanical stress-induced cardiac hypertrophy. Diabetes Res Clin Pract. 1996;30(suppl):107-111.
33.
Zou Y., Komuro I., Yamazaki T., et al. Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes. J Biol Chem. 1996;271(52): 33592-33597.
34.
Naveri L.The role of angiotensin receptor subtypes in cerebrovascular regulation in the rat. Acta Physiol Scand Suppl. 1995;630:1-48.
35.
Urata H., Healy B., Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts . Circ Res. 1990;66(4):883-890.
36.
Senbonmatsu T., Saito T., Landon EJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J. 2003;22(24):6471-6482.
37.
Gohike P., Linz W., Scholkens BA, et al. Angiotensin-converting enzyme inhibition improves cardiac function . Role of bradykinin. Hypertension. 1994;23(4):411-418.
38.
Guo X., Wang J., Elimban V., Dhalla NSBoth enalapril and losartan attenuate sarcolemmal Na+-K+ ATPase remodeling in failing rat heart due to myocardial infarction. Can J Physiol Pharmacol. 2008;86(4):139-147.
39.
Wang J., Guo X., Dhalla NSModification of myosin protein and gene expression in failing hearts due to myocardial infarction by enalapril and losartan. Biophys Biochem Acta. 2004;1690(2):177-184.
40.
Shao Q., Ren B., Elimban V., Tappia PS, Takeda N., Dhalla NSModification of sarcolemmal Na+-K+ ATPase and Na+-Ca2+ exchanger expression in heart failure by blockade of reninangiotensin system. Am J Physiol Heart Circ Physiol. 2005; 288(6):H2637-H2646.
41.
Hirata Y., Hayakawa H., Kakoki M., et al. Nitric oxide release from kidneys of hypertensive rats treated with imidapril. Hypertension. 1996;27(3 pt 2):672-678.
